FBTIX — Fidelity Advisor Biotechnology Fund
Data updated: 2026-06-26
FBTIX — Fidelity Advisor Biotechnology Fund data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $1.90B AUM · 0.71% expense ratio · 52.6% 1-yr return. From SEC regulatory filings.
FBTIX Fund Overview
FBTIX — Fidelity Advisor Biotechnology Fund is a US mutual fund managed by Fidelity Advisor Series VII, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US mutual fund
- Manager: Fidelity Advisor Series VII
- Category: United States Health Care Equity
- Assets under management: $1.90B
- 1-year return: 52.6%
- Ticker: FBTIX
- SEC CIK: 0000315700
- SEC series ID: S000005321
- Share class ID: C000014523
FBTIX Holdings
Top 10 holdings of Fidelity Advisor Biotechnology Fund by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Abbvie, Inc. | 14.83% |
| Alnylam Pharmaceuticals, Inc. | 5.52% |
| Gilead Sciences, Inc. | 5.42% |
| Insmed, Inc. | 3.51% |
| Cogent Biosciences, Inc. | 3.45% |
| Dianthus Therapeutics, Inc. | 3.37% |
| Spyre Therapeutics, Inc. | 3.33% |
| Ascendis Pharma A/s | 3.24% |
| Argenx SE | 3.17% |
| Biogen, Inc. | 2.92% |
FBTIX Portfolio Allocation
Asset-class allocation of Fidelity Advisor Biotechnology Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.2% |
| Cash & Equivalents | 3.3% |
| Fixed Income | 0.1% |
FBTIX Performance
Total returns for FBTIX (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 4.4% |
| 1 year | 52.6% |
| 3 years (annualised) | 20.3% |
| 5 years (annualised) | 9.3% |
FBTIX Risk Information
Risk metrics for FBTIX, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 18.1%
FBTIX Costs and Fees
FBTIX costs about $71 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.71%
- Gross expense ratio: 0.71%
- Portfolio turnover: 51%
- Brokerage commissions: 3.94 bps of average net assets (SEC N-CEN)
FBTIX Cashflows
Over the 12 months to 2026-04, Fidelity Advisor Biotechnology Fund had net outflows of $97.44M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-04 | −$7.05M |
| 2026-03 | −$5.78M |
| 2026-02 | −$3.95M |
| 2026-01 | −$3.40M |
| 2025-12 | $25.80M |
| 2025-11 | $6.52M |
FBTIX Debt Constituents
Largest debt holdings of Fidelity Advisor Biotechnology Fund by percentage of net assets, from the latest SEC N-PORT filing.
| Debt holding | % of net assets |
|---|---|
| Wugen, Inc. | 0.05% |
| Kartos Therapeutics, Inc. | 0.01% |
FBTIX Prospectus and SEC Filings
Official Fidelity Advisor Biotechnology Fund filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.